[HTML][HTML] A booster dose of Delta× Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
IJ Lee, CP Sun, PY Wu, YH Lan, IH Wang… - Journal of Biomedical …, 2022 - Springer
Background With the continuous emergence of new SARS-CoV-2 variants that feature
increased transmission and immune escape, there is an urgent demand for a better vaccine …
increased transmission and immune escape, there is an urgent demand for a better vaccine …
[HTML][HTML] ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants
N van Doremalen, JE Schulz, DR Adney… - Nature …, 2022 - nature.com
Abstract ChAdOx1 nCoV-19 (AZD1222) is a replication-deficient simian adenovirus–
vectored vaccine encoding the spike (S) protein of SARS-CoV-2, based on the first …
vectored vaccine encoding the spike (S) protein of SARS-CoV-2, based on the first …
[HTML][HTML] Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
S Chalkias, F Eder, B Essink, S Khetan, B Nestorova… - Nature medicine, 2022 - nature.com
Updated immunization strategies are needed to address multiple severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variants. Here we report interim results from an …
syndrome coronavirus 2 (SARS-CoV-2) variants. Here we report interim results from an …
[HTML][HTML] Omicron BA. 1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial
IT Lee, CA Cosgrove, P Moore, C Bethune… - The Lancet Infectious …, 2023 - thelancet.com
Background The omicron BA. 1 bivalent booster is used globally. Previous open-label
studies of the omicron BA. 1 (Moderna mRNA-1273.214) booster showed superior …
studies of the omicron BA. 1 (Moderna mRNA-1273.214) booster showed superior …
[HTML][HTML] Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to …
DW Hawman, K Meade-White, C Clancy, J Archer… - …, 2022 - thelancet.com
Background In late 2021, the SARS-CoV-2 Omicron (B. 1.1. 529) variant of concern (VoC)
was reported with many mutations in the viral spike protein that were predicted to enhance …
was reported with many mutations in the viral spike protein that were predicted to enhance …
[HTML][HTML] BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19
GMN Behrens, J Barros-Martins, A Cossmann… - Nature …, 2022 - nature.com
Heterologous prime/boost vaccination with a vector-based approach (ChAdOx-1nCov-19,
ChAd) followed by an mRNA vaccine (eg BNT162b2, BNT) has been reported to be superior …
ChAd) followed by an mRNA vaccine (eg BNT162b2, BNT) has been reported to be superior …
[PDF][PDF] SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals
SI Richardson, VS Madzorera, H Spencer… - Cell Host & Microbe, 2022 - cell.com
Summary The SARS-CoV-2 Omicron variant escapes neutralizing antibodies elicited by
vaccines or infection. However, whether Omicron triggers cross-reactive humoral responses …
vaccines or infection. However, whether Omicron triggers cross-reactive humoral responses …
[HTML][HTML] Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants
F Wussow, M Kha, T Kim, M Ly, M Yll-Pico, S Kar… - npj Vaccines, 2023 - nature.com
Abstract Emerging SARS-CoV-2 Omicron subvariants continue to disrupt COVID-19 vaccine
efficacy through multiple immune mechanisms including neutralizing antibody evasion. We …
efficacy through multiple immune mechanisms including neutralizing antibody evasion. We …
[HTML][HTML] Immune imprinting and implications for COVID-19
Immunological memory is the key source of protective immunity against pathogens. At the
current stage of the COVID-19 pandemic, heterologous combinations of exposure to viral …
current stage of the COVID-19 pandemic, heterologous combinations of exposure to viral …
[HTML][HTML] Covid-19 boosters—where from here?
PA Offit - New England Journal of Medicine, 2022 - Mass Medical Soc
On December 10, 2020, Pfizer presented results from a 36,000-person, two-dose,
prospective, placebo-controlled trial of its Covid-19 messenger RNA (mRNA) vaccine …
prospective, placebo-controlled trial of its Covid-19 messenger RNA (mRNA) vaccine …